The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Occam,you do go down the all doom and gloom route very quickly again.
"Maybe the regulator froze the accounts" sounds rather hysterical.
I appreciate you have done a ballpark, all in figure. But that does value the FCF as a whole at less than the FCF of a component from another report.
I only took the repayment period from the CPR to estimate the FCF, I appreciate there is no allowance for any purchase price.
Similarly,if one were to consider the NPV from the report over the 11 years, there is a wuestion as to whether that return over that time period is good or bad.
I think my point is that,by other reports, I feel you are potentislly assigning the costs but no benefits of MT in you calculations.
Not that there is anything wrong with that of course. It's all estimates made from assumptions until we have further information
Interesting figures Fr.J.H
What FCF are you assigning between NKT & MT? I note the CPR for NKT had a 3yr payback period for NKT @8.33% dr. So gives a FCF of around $220 for NKT alone.
Whilst I appreciate prices etc have moved, that is higher than your FCF estimate for MT & NKT combined.
Nice to see some calculations as opposed to mudslinging for a change 🥳
You seem to ignore the reality that significant funds have been raised at a premium to current share price. Whilst it is unusual, it is happening here.
I did state "IF the company is successful" when I said the conversion would be almost guaranteed. You wouldn't sit on 5% interest when you could exercise and sell for 10x +.
Any in the money option (be it a call, put or conversion) is likely to be exercised when it is deemed better than holding the option (be that things are going to go up or get out before they go down).
@Occam. But the dilution from loan conversion is finite and known. In the event the company is a success, it's pretty much guaranteed to happen. Smorris makibg a drama out if it shows either startling ignirance or deliberate trolling.
Your "math" only applies when shares are issued below the current SP (like with the loan conversion). If shares are issued at a price higher than the current SP (as has happened in the funding rounds) the SP would increase.
Dan is suggesting that, whilst suspended, the funding rounds continue at abive current SP, hence upon relist, there would be an increase.
There is no current intent to issue $100m @ $0.10, the last issue was at £11 or so. So statements like "...wipes you out" are clearly ill informed for the actual situation at present